8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
1/58
DRUG RESISTANTTUBERCULOSIS
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
2/58
• Tuberculosis is a bacterial infection caused by
Mycobacterium TB
• The disease primarily aects lungs(pulmonary TB)
• Other organs include intestine, meninges, bones and
joints, lymph glands and skin
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
3/58
DRUG RESISTANCE
Temporary/permanent capacity of the organism their progeny to remain !iable/to multiply inthe presence of the concentration of the drugthat "ould normally destroy/inhibit the gro"th
of other cells
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
4/58
Types of #rug $esistant TB
MDR TB does not simply mean resistance to more thadrug, it speci%cally means resistance to at least bothisonia&id (') and rifampin ($)
XDR-TB is a rare type of M#$TB that is resistant to rifampicin, plus any +uorouinolone and at least one othree injectable secondline drugs(amikacin, kanamyccapreomycin)
TDR-TB refers to M-TB clinical strains that strains thasho" in !itro resistance to all %rst and second line dru
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
5/58
.mergence of drug resistance
• treptomycin "as introduced in 0123 for the treatmentand the %rst case of Mresistant TB "as reported in 01
• *' "as introduced in 0156 and "as used alone or incombination "ith M/ 789 by the British Medical $eseacouncil
• The %rst case of M#$TB "as reported in 011: "ithresistance to *' and rifampicin in *e";ork
• The %rst case of
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
6/58
• The presence of T#$TB "as %rst obser!ed in t"o pin taly in 6::>, the second report came from ran
•
n jan 6:06 there "as a report of 2 cases of T#$TB ndia
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
7/58
8s per ?'O, about >-4@ of ne" TB patients in the "oha!e M#$TB-
8bout 1@ of M#$TB cases ha!e resistance to t"o othclasses of drugs, or are eAtensi!ely drug resistant TB(TB)
By March 6:0>, 2 countries had reported at least onTB case
?'O estimates that there "ere about :-5 million ne"TB cases in the "orld in 6:00
8bout 3:@ of the cases occurred in Bra&il, 9hina, ndi$ussia outh 8frica alone (CB$9D countries)
2@ of patients "ith M#$TB and 666@ of
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
8/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
9/58
Eenesis of M#$TB
$esistance is a manmade ampli%cation of a naturalphenomenon-
nadeuate drug deli!ery is main cause of secondarresistance-
econdary drug resistance is the main cause of primdrug resistance due to transmission of resistant stra
M#$ due to spontaneous mutations is not possible agenes encoding resistance for anti TB are unlinked-
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
10/58
Strains with geneticdrug resistance
Wild M. TB strain
Acquired drugresistance
Primary drugresistance
Spontaneous mutation
Selection: inadequate treatment
Transmission
Development o anti!tu"erculosis drug resistance
Pa"los!Mende# et al. W$%& '(()
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
11/58
Mechanism of resistance
*' – 9hromosomally mediated
– Foss of catalase/peroAidase
– Mutation in mycolic acid synthesis
– $egulators of peroAide response
$ifampin – $educed binding to $*8 polymerase9lusters of mutations at C$ifampin $esistance
#etermining $egionD ($$#$)
– $educed 9ell "all permeability
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
12/58
8ntiTB #rugs
First-Line
Second-Lin
• (') sonia&id
• ($) $ifampin
•
(G)7yra&inamide
• (.).thambutol
• treptom
• 9ycloser
• .thionam• 8mikacin
• 9ipro+oA
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
13/58
7re!alence of drugresistant
in ndia• nitial M#$TB is probably !ery lo"
• M#$TB is more common in pre!iously treated TBpatients
• 8cuired resistance to $ifampicin >>>5@
• 8cuired resistance to *'5:55@
• trains resistant to $ifampicin are usually resistant *' "hereas !ice !ersa may not be al"ays true
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
14/58
•#rugresistant TB is transmitted the same "
drugsusceptible TB•#rug resistance is di!ided into t"o typesH
- Primar resistance refers to cases initiallyinfected "ith resistant organisms
- Ac!"ired resistance de!elops during TB th
Drug-Resistant TB
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
15/58
• Initia# resistance- presence of drug resistato one/more antiTB drugs in a ne" TB patien
"ho presents to a TB centre
• C$ronic %atient patient "ho remains smeapositi!e after completing a ?'O retreatmenregimen under super!ision
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
16/58
Persons at Increased Ris& 'orDr"( Resistance
•'istory of treatment "ith TB drugs
•9ontacts of persons "ith drugresistant T
•mears or cultures remain positi!e despimonths of TB treatment
•$ecei!ed inadeuate treatment regimensI6 "eeks
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
17/58
9linicians eAperience many challenges in the managemof patients "ith #$TB - uccess of treatment depends
0- Juality diagnosis testing
6- Medications , /. and drug regimens
>- The patient and the programme
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
18/58
9linical signi%cance of drug
resistant TB• Treatment failure rate is 53 fold
• n case of resistance to *'/ treptomycin , the TB csuccessfully treated "ith 3 months of short coursechemotherapy
• $esistance to rifampicin is a serious problem• 8bout 4:1:@ of *' $ifampicin resistant bacilli
not respond/relapsed to treatment "ith short coursechemotherapy
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
19/58
#iagnosis of drugresistant T• Kail to respond / deteriorate• 9linical criteria to con%rm failure / relapse after 6 cours
chemotherapy at least one of "hich is directly obser!ed
• 9on%rm "hether the diagnosis "as correct
• $epeat sputum 8KB and 9
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
20/58
Management of drug resistant T
(#OTplus regime)• The regimen should include at least > drugs for "hich
patientLs organism ha!e pro!en in!itro susceptibility preferably that ha!e not been used to treat the patient
• 8fter diagnosis, the treatment of M#$TB is initiated a
designated #OT7lus sites, "hich are established in tcare centres (M9/large speciality hospitals)
• 7retreatment e!aluation since the drugs used are knoproduce ad!erse eects
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
21/58
7retreatment e!aluation
0- #etailed history
6- 'eight, "eight
>- 9B9
2- Blood sugar
5- FKT
3- TKT
4- =rine $/. microscopy
- 7regnancy test
1- 9
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
22/58
$egimen for M#$TB
INTENSI)E P*ASE+,-mont$s.
anamycin, le!o+oAacin, ethionamide, pyra&inamide,ethambutol, cycloserine
CONTINUATION P*ASE+/0 mont$s.
Fe!o+oAacin, ethionamide, ethambutol, cycloserine
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
23/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
24/58
• 8s single daily dose under super!ision
• On sundays, the oral drugs "ill be administeredunsuper!ised "hereas injection anamycin "ill be o
• f any intolerance occurs, ethionamide, cycloserine a78 may be split into t"o, the morning doses taken super!ision e!ening doses selfadministered
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
25/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
26/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
27/58
$egimen for
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
28/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
29/58
• 8ll drugs are to be gi!en on a daily basis
• nj- 9apreomycin are to be gi!en for 3 days / "eek (nunday)
• 8ll morning doses are to be super!ised by the #OTpro!iders eAcept on sundays
• Oral medicines for are gi!en on aturday to be takenthe patient at home
• .mpty blisters of medicines taken on unday are to collected by #OT pro!ider
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
30/58
• #irect obser!ation of treatment remains e!en moreimportant in
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
31/58
Treatment of TB during pregnanc
•
Treated "ith *', $ifampicin and .thambutol for 6 monfollo"ed by *' $ifampicin for an additional 4 month
• f susceptible to *' $ifampicin, ethambutol can be safter the %rst month
• 7yra&inamide should be used only if resistance to other are documented
• treptomycin is 9/ in pregnancy as it may cause congendeafness
• Those taking *' should recei!e pyridoAin 0:65 mg oronce a day to pre!ent peripheral neuropathy
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
32/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
33/58
9hildhood TB
• TB in children is mainly d/t failure of TB control in a
• 8n infant "hose mother has sputum smear positi!e has a high chance of becoming infected
• Because of less de!eloped immune system, children
5 years of age are more prone to de!elop the diseasemostly "ithin 6 years follo"ing infection
• 02 yrs
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
34/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
35/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
36/58
#O8E. OK #$=E
• $ifampicin N 0:06mg/kg
• *' 0:mg/kg
• .thambutol 6:65 mg/kg
• 7G8 >:>5mg/kg
• treptomycin 05mg/kg
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
37/58
' TB•
The ' !irus damages the bodyLs natural defences theimmune systemand accelerates the speed at "hich TBprogresses from harmless infection to life threatening co
• ' TB interact in se!eral "ays
$eacti!ation of latent infection 65>: times more risk,because of the stoppage of "orking of the immune system
' 7rimary infection ' patients are at risk of being ne"l
infected "ith TB because their "eakened immune systemthem more !ulnerable
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
38/58
$ecurring infection ' patients "ho ha!e been cureTB infection are more at risk of de!eloping TB again
DIAGNOSIS OF TB IN *I) PATIENTS
n ' patients at early stages, the symptoms of TB are sto those "ithout ' infection- 'o"e!er the diagnosis of using the standard diagnostic tools can be diicult in thead!anced ' infection because,
0- putum smear N!e, sputum culture to con%rm6- Tuberculin test N!e
>- Fess ca!itations in the 9
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
39/58
DIAGNOSIS OF *I) IN TB PATIENTS
• n areas "here there is high pre!alence of ', 'testing should be systematically oered to all TB
patients, including children• erological testing
• 7atients should be counselled on beha!iour risk andmethods to pre!ent transmitting or acuiring the inf
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
40/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
41/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
42/58
Bedauiline Na no!el promisindisco!ery in M#$TB
• #isco!ered in 6::2 by Pohnson Pohnson !ia screening protomore than 4:,::: chemicals by inhibition of gro"th againstmycobacterium smegmatis, a more rapidly gro"ing mycobactcompared to MTB
• Kirst described at the nter science 9onference on 8ntimicrob
agents and chemotherapy (9889) in 6::2• MO8 inhibit proton pump of 8T7 synthase in MTB- 8T7 synt
an en&yme that is essential for the generation of energy in MTBedauiline binds to the csubunit of 8T7 synthase inhibiting 8synthesis causing death of MTB
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
43/58
• ndication as a part of combination therapy in adu"ith M#$TB "hen other alternati!es are not a!aila
• #osage and administration initial dose of 2::mg odaily for 6 "eeks follo"ed by 6::mg > times per "e66"eeks- t is supplied as 0::mg tablets to be takenfood and s"allo"ed "hole "ith "ater
• 8d!erse eects nausea, arthralgia, diarrhoea, paieAtremities and hyperuricemia
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
44/58
8cuired resistance of MTB toBedauiline
• denti%ed in 6:02
• #ue to mutations in $!o34 , a transcriptional repreof the genes encoding Mmp5Mm7F5 eQuA pump- based resistance "as identi%ed in paired isolates fro
patients treated "ith B#J as "ell as in mice, in "hic"as con%rmed to decrease the bactericidal eicacy- eQuA inhibitors !erapamil reserpine decreasesminimum inhibitory concentration of B#J but failedincrease the bactericidal eect of B#J in mice "aunable to re!erse the eQuA based resistance in!i!o
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
45/58
• n addition to B#J, delamanid and line&olid are apprby the = Kood and #rug 8dministration(K#8) and t.uropean Medicines 8gency that may oer therapeu
solution to T#$TB
• n a recent update on T#$TB, 05 cases "ith resistaall drugs tested ha!e been reported and 5 patients d
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
46/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
47/58
7re!ention of #$TB
• nitial treatment "ith standardi&ed regimens ('$G.
• #irectly obser!ed therapy (#OT)
• #rug susceptibility testing for all retreatment cases
• nfection control precautions
• Monitor drug resistance through sur!eys• .ecti!e contact management
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
48/58
TO7 TB T$8T.E; • Faunched in 6::3
• t is to be implemented o!er the neAt 0: years asdescribed in the Elobal plan to stop TB in 6::36:05
• t focuses on 5 principal indicators that are used tomeasure the implementation and the impact of TB c case detection, treatment, success, incidence,
pre!alence and deaths
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
49/58
Targets
• By 6:05 the global burden of TB "ill be reduced byrelati!e to 011: le!els- This means reducing pre!ale
05: per 0::::: or lo"er and deaths to 05 per 0::: year or lo"er by 6:05
• The number of people dying from TB in 6:05 shouldless than approAimately 0 million including thosecoinfected "ith '
•
By 6:5: the global incidence of TB disease "ill be lthan or eual to 0 case per million population per ye
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
50/58
9OM7O*.*T OK T'. T$8T.E; 8*#M7F.M.*T8TO* 877$O89'.
0- 7ursuing high uality #OT eApansion and enhanc
•. 7olitical commitments "ith increased and sustained%nancing
•. 9ase detection through ualityassured bacteriology
•. tandardi&ed treatment "ith super!ision and patiensupport
•. 8n eecti!e drug supply and management system
•. Monitoring and e!aluation system and impactmeasurement
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
51/58
6- 8ddressing TB/', M#$TB and other challenges
• mplement collaborate TB/' acti!ities
• 7re!ent and control M#$TB
• 8ddress prisoners, refugees, other high risk groups andspecial situations
>- 9ontributing to health system strengthening
• 8cti!ely participate in eorts to impro!e system "ide phuman resources, %nancing, management, ser!ice deli!
and information system• hare inno!ations that strengthen health systems, inclu
the practical approach to lung health(78F)
• 8dapt inno!ations from other %elds
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
52/58
2- .ngaging all care pro!iders
• 7ublicpublic and publicpri!ate miA approaches
•
mplement international standards for TB care5- .mpo"ering people "ith TB and communities
• 8d!ocacy , communication and social mobilisation
• 9ommunity participation in TB care
• 7atientsL charter for TB care
3- .nabling and promoting research• 7rogramme based operational research
• $esearch to de!elop ne" diagnostics, drugs and !ac
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
53/58
$*T97 daily treatment regim
T%e o' TBcases
Treatmentre(imen IP
Treatmentre(imenCP
*.? 6'$G. 2'$.
7$.O=F;T$.8T.#
6'$G.R0'$. 5'$.
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
54/58
#aily dosage schedule for adu 2ei($t
cate(or
N"m3er
o'
cons"med
ta3#ets to
3e
in4ection
stre
cin
7 97
'$G. '$.
45/05:/2::/ 645mg/tab
45/05:/645 mg/tab Eram
65>1 kg 6 6 :-5 g
2:52 kg > > :-45 g
5531 kg 2 2 0 g
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
55/58
THE END TB STRATEGY 2016-2035VISION A world free of TB - Zero deaths, disease and suering due to TB
GOA! En" t#e G$%&a$ TB E'i"e(i)*I!ESTONES +OR 2025 75% reduction in TB deaths (compared with 2!5" 5% reduction in TB incidence rate (less than 55 T!, population" #o aected families facing catastrophic costs due
TARGETS +OR 2035 $5% reduction in TB deaths (compared with 2!5" $% reduction in TB incidence rate (less than ! TB ca
!, population" #o aected families facing catastrophic costs due to T
,RINI,!ES - o&ernment stewardship and accounta'ilit, with monitoring a - )trong coalition with ci&il societ organi*ations and communit - +rotection and promotion of human rights, ethics and euit - Adaptation of the strateg and targets at countr le&el, with gcolla'oration
• ,I!!ARS AND O*,ONENTS
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
56/58
• 1. INTEGRATED/ ,ATIENT-ENTRED ARE AND ,REVENTIONA .arl diagnosis of TB including uni&ersal drug suscepti'ilit testing/ and sstemof contacts and high-ris0 groupsB Treatment of all people with TB including drug-resistant TB/ and patient supporA 1olla'orati&e TB34 acti&ities and management of comor'iditiesB +re&enti&e treatment of persons at high-ris0/ and &accination against TB
• 2. BO!D ,O!IIES AND S,,ORTIVE SYSTE*SA +olitical commitment with adeuate resources for TB care and pre&entionB .ngagement of communities, ci&il societ organi*ations, and pu'lic and pri&ate1 6ni&ersal 3ealth 1o&erage polic and regulator framewor0s for case noticatiregistration,
ualit and rational use of medicines, and infection control8 )ocial protection, po&ert alle&iation and actions on other determinants of TB
• 3. INTENSI+IED RESEARH AND INNOVATIONA 8isco&er, de&elopment and rapid upta0e of new tools, inter&entions and strateB 9esearch to optimi*e implementation and impact, and promote inno&ations
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
57/58
8/18/2019 DRUG RESISTANT TUBERCULOSIS.pptx
58/58
T'8* ;O=